<DOC>
	<DOCNO>NCT02858388</DOCNO>
	<brief_summary>The goal study investigate active agent Sinuclean Nebules efficacious treatment pediatric exudative otitis medium , compare saline . Sinuclean Nebules solution cucurbitacins B , D , I , E ( glycosylated triterpenes ) 45 mcg , extract Ecballium Elaterium .</brief_summary>
	<brief_title>Sinuclean Nebules 45 Treatment Pediatric Exudative Otitis Media</brief_title>
	<detailed_description>Eligible pediatric subject diagnosis mono bi-lateral exudative otitis medium ( obtain otorhinolaryngologic endoscopic examination , tympanogram tonal audiometry ) , randomize treatment Sinuclean Nebules 45 saline . Treatment administer trained caregiver nebulizer ( Rinowash Nasal Shower ) : one nebulization/nostril/day two cycle 10 consecutive day . Cycles interrupt period 7 day . Visits 1 Baseline T0 : confirmation eligibility , randomization , train caregiver , dispensation blind therapy two cycle , delivery clinical diary . Visit 2 10 day therapy + 7 day interval : phone call check adverse event , therapy adherence , concomitant disease treatment , prescribe second cycle therapy . Visit 3 End Study : assessment exudative otitis medium otorhinolaryngologic endoscopic examination , tympanogram tonal audiometry , verification subject 's clinical diary .</detailed_description>
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<mesh_term>Otitis Media Effusion</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Documented diagnosis mono bilateral exudative otitis medium , perform day recruitment week , endotympanic effusion present least 3 month , hear loss . The diagnostic criterion type B tympanogram least one two ear . The criterion integrate ) tonal audiometry demonstrate bilateral monolateral deficit ( loss 20dB average 0.51.2 4Khz best ear pure tone audiometry ) ; 13 yo subject audiometry behavioural b ) otorhinolaryngologic examination endoscopy otologic , rhinosinusal pharyngeal district . 1 . Outcomes adenotonsillectomy 2 . Velopalatal insufficiency , cleave lip cleft palate . 3 . Hearing loss perceptual , mixed type . 4 . Clinical condition ( systemic disease ) may interfere evaluation safety clinical effectiveness product investigation , example : diabetes mellitus , heart disease , chronic renal failure , active systemic infection ) 5 . Assumption , study drug may interfere assessment product object clinical investigation . 6 . Possibility need treatment study drug allow , example : antibiotic longterm prophylaxis , immunosuppressant , corticosteroid . 7 . Regular intake steroid four week precede date admission visit . 8 . Viral allergic rhinitis , active effusion . 9 . Down Syndrome 10 . Diagnosis immotile cilia syndrome 11 . Condition immune deficiency disease otherwise . 12 . Cystic Fibrosis . 13 . Dental malocclusion 14 . Other disease organ system , , opinion investigator , may interfere purpose study procedure . 15 . Not vaccinated subject , clinical history varicella contact , 4 week admission visit , people may suffer chicken pox Zoster . 16 . Psychic condition incompatible participation research . 17 . History intolerance allergy component Sinuclean Nebules . 18 . Medical surgical intervention may prejudice complete execution trial , 4 week precede signing informed consent . 19 . Imminence medicalsurgical procedure jeopardize completion trial . 20 . Participation course clinical investigation , terminate within 30 day start trial . 21 . Previous randomization study 22 . Be first secondgrade relative member Site study staff .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Otitis Media Effusion</keyword>
	<keyword>Exudative otitis medium</keyword>
</DOC>